---
title: "復宏漢霖漢斯狀新增適應症藥品註冊申請獲受理"
description: "復星醫藥公佈，控股子公司復宏漢霖就斯魯利單抗注射液 (商品名：漢斯狀) 新增適應症 (即聯合含鉑化療新輔助，在手術後輔助治療，用於 PD-L1 陽性的、可手術切除的胃癌患者) 的藥品註冊申請獲國家藥品監督管理局受理，並已獲納入優先審評程序。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/269621083.md"
published_at: "2025-12-14T09:24:57.000Z"
---

# 復宏漢霖漢斯狀新增適應症藥品註冊申請獲受理

> 復星醫藥公佈，控股子公司復宏漢霖就斯魯利單抗注射液 (商品名：漢斯狀) 新增適應症 (即聯合含鉑化療新輔助，在手術後輔助治療，用於 PD-L1 陽性的、可手術切除的胃癌患者) 的藥品註冊申請獲國家藥品監督管理局受理，並已獲納入優先審評程序。

復星醫藥 (02196.HK) 公佈，控股子公司復宏漢霖 (02696.HK) 就斯魯利單抗注射液 (商品名：漢斯狀) 新增適應症 (即聯合含鉑化療新輔助，在手術後輔助治療，用於 PD-L1 陽性的、可手術切除的胃癌患者) 的藥品註冊申請獲國家藥品監督管理局受理，並已獲納入優先審評程序。

### Related Stocks

- [02696.HK - 復宏漢霖](https://longbridge.com/zh-HK/quote/02696.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Shanghai Henlius Biotech Doses First Patient in Phase 1b/2 Trial of HLX43 Combination for Advanced Colorectal Cancer | Shanghai Henlius Biotech Inc. has initiated a phase 1b/2 clinical trial for HLX43, an anti-PD-L1 antibody-drug conjugate | [Link](https://longbridge.com/zh-HK/news/275577160.md) |
| Shanghai Henlius Biotech Inc announces phase 3 trial success for Hansizhuang in gastric cancer | Shanghai Henlius Biotech Inc. announced the success of its phase 3 clinical trial for HANSIZHUANG (serplulimab injection | [Link](https://longbridge.com/zh-HK/news/260398601.md) |
| Towa Pharmaceutical (TSE:4553) Margin Firmness Reinforces Defensive Earnings Narrative In Q3 2026 | Towa Pharmaceutical (TSE:4553) reported solid Q3 2026 results with revenue of ¥73.6b and net income of ¥8.9b, reflecting | [Link](https://longbridge.com/zh-HK/news/275991027.md) |
| Hangzhou Jiuyuan Gene Engineering IND Application for JY54 Injection Accepted by CDE | Hangzhou Jiuyuan Gene Engineering Co. Ltd. has announced that its IND application for JY54 Injection has been accepted b | [Link](https://longbridge.com/zh-HK/news/275289286.md) |
| Fosun Pharma Unit Gets China Acceptance for Anesthesia Drug Application | Fosun Pharma Unit Gets China Acceptance for Anesthesia Drug Application | [Link](https://longbridge.com/zh-HK/news/275893661.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。